Pivotal Phase III study demonstrates substantial symptom relief in patients with systemic juvenile idiopathic arthritis treated with canakinumab

被引：0
|
作者：
不详
机构：
来源：
EXPERT REVIEW OF CLINICAL IMMUNOLOGY | 2011年 / 7卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：721 / 721
页数：1
相关论文
共 50 条
  • [1] TREATING TO TARGET WITH CANAKINUMAB IN PATIENTS WITH ACTIVE SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: RESULTS FROM THE LONG-TERM EXTENSION THE PHASE III PIVOTAL TRIAL
    Ruperto, N.
    Brunner, H. I.
    Quartier, P.
    Constantin, T.
    Alexeeva, E.
    Kone-Paut, I.
    Marzan, K.
    Wulffraat, N.
    Schneider, R.
    Padeh, S.
    Chasnyk, V.
    Wouters, C.
    Kuemmerle-Deschner, J. B.
    Kallinich, T.
    Lauwerys, B.
    Haddad, E.
    Nasonov, E.
    Trachana, M.
    Vougiouka, O.
    Leon, K.
    Speziale, A.
    Lheritier, K.
    Martini, A.
    Lovell, D.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 401 - 402
  • [2] Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis
    Sun, Haiying
    Van, Linh M.
    Floch, David
    Jiang, Xuemin
    Klein, Ulf R.
    Abrams, Ken
    Sunkara, Gangadhar
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (12): : 1516 - 1527
  • [3] Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials
    Ruperto, Nicolino
    Brunner, Hermine I.
    Quartier, Pierre
    Constantin, Tamas
    Wulffraat, Nico M.
    Horneff, Gerd
    Kasapcopur, Ozgur
    Schneider, Rayfel
    Anton, Jordi
    Barash, Judith
    Berner, Reinhard
    Corona, Fabrizia
    Cuttica, Ruben
    Fouillet-desjonqueres, Marine
    Fischbach, Michel
    Foster, Helen E.
    Foell, Dirk
    Radominski, Sebastiao C.
    Ramanan, Athimalaipet V.
    Trauzeddel, Ralf
    Unsal, Erbil
    Levy, Jeremy
    Vritzali, Eleni
    Martini, Alberto
    Lovell, Daniel J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (12) : 1710 - 1719
  • [4] MAINTENANCE OF EFFICACY BY CANAKINUMAB TREATMENT IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS PATIENTS
    Wulffraat, N. M.
    Ruperto, N.
    Brunner, H. I.
    Oliveira, S.
    Uziel, Y.
    Nistala, K.
    Cimaz, R.
    Ferrandiz, M. A.
    Flato, B.
    Gamir, M. L.
    Kone-Paut, I.
    Gaillez, C.
    Lheritier, K.
    Abrams, K.
    Martini, A.
    Lovell, D. J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 130 - 130
  • [5] Efficacy and Safety of Canakinumab in Patients with Active Systemic Juvenile Idiopathic Arthritis and Fever: Results From Two Pivotal Phase 3 Trials.
    Brunner, Hermine I.
    Ruperto, Nicolino
    Quartier, Pierre
    Constantin, Tamas
    Wulffraat, Nico
    Horneff, Gerd
    Brik, Riva
    McCann, Liza
    Ozdogan, Huri
    Rutkowska-Sak, Lidia
    Schneider, Rayfel
    Berkun, Yackov
    Calvo, Inmaculada
    Erguven, Muferet
    Goffin, Laurence
    Hofer, Michael
    Kallinich, Tilmann
    Lheritier, Karine
    Abrams, Ken
    Stancati, Andrea
    Lovell, D. J.
    Martini, Alberto
    [J]. ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S326 - S327
  • [6] Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab
    Grom, Alexei A.
    Ilowite, Norman T.
    Pascual, Virginia
    Brunner, Hermine I.
    Martini, Alberto
    Lovell, Daniel
    Ruperto, Nicolino
    Leon, Karolynn
    Lheritier, Karine
    Abrams, Ken
    [J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68 (01) : 218 - 228
  • [7] Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis Patients Treated with Canakinumab: Results from Phase 3 Trial Program
    Grom, Alexei A.
    Brunner, Hermine I.
    Ruperto, Nicolino
    Martini, Alberto
    Lovell, Daniel
    Pascual, Virginia
    Lheritier, Karine
    Leon, Karolynn
    Abrams, Ken
    Ilowite, Norman
    [J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [8] The safety of canakinumab in systemic juvenile idiopathic arthritis and autoinflammatory diseases in pediatric patients: a multicenter study
    Coskuner, Taner
    Caglayan, Senguel
    Akgun, Ozlem
    Torun, Ruya
    Yayla, Emine Nur Sunar
    Bagrul, Ilknur
    Kilbas, Gulsah
    Yener, Gulcin Otar
    Kose, Hulya
    Ozturk, Kubra
    Baba, Ozge
    Cakan, Mustafa
    Demir, Ferhat
    Sonmez, Hafize Emine
    Kalyoncu, Mukaddes
    Kilic, Sara Nsebnem
    Yuksel, Selcuk
    Baglan, Esra
    Bakkaloglu, Sevcan A.
    Unsal, Erbil
    Aktay Ayaz, Nuray
    Sozeri, Betul
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2023, 23 (12) : 1299 - 1306
  • [9] Canakinumab treatment shows maintained efficacy in systemic juvenile idiopathic arthritis patients
    NM Wulffraat
    N Ruperto
    HI Brunner
    S Oliveira
    Y Uziel
    K Nistala
    R Cimaz
    MA Ferrandiz
    B Flato
    M Gamir
    I Kone-Paut
    C Gaillez
    K Lheritier
    K Abrams
    A Martini
    D Lovell
    [J]. Pediatric Rheumatology, 12 (Suppl 1)
  • [10] Efficacy of Canakinumab in Systemic Juvenile Idiopathic Arthritis Patients Previously Exposed to Biologics
    Brunner, Hermine I.
    Ruperto, Nicolino
    Quartier, Pierre
    Constantin, Tamas
    Berkun, Yackov
    Calvo-Penedes, Inmaculada
    Erguven, Mueferet
    Goffin, Laurence
    Hofer, Michael
    Kallinich, Tilmann
    Oliveira, Sheila
    Uziel, Yosef
    Viola, Stefania
    Nistala, Kiran
    Wouters, Carine
    Leon, Karolynn
    Speziale, Antonio
    Lheritier, Karine
    Junge, Guido
    Lovell, Daniel
    Martini, Alberto
    [J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
12345